MNPR
Monopar Therapeutics Inc. NASDAQ Listed Dec 19, 2019$62.43
Mkt Cap $417.8M
52w Low $28.40
44.4% of range
52w High $105.00
50d MA $55.85
200d MA $62.98
P/E (TTM)
-28.8x
EV/EBITDA
3663.4x
P/B
0.0x
Debt/Equity
0.0x
ROE
-10.0%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
1.66
50d MA
$55.85
200d MA
$62.98
Avg Volume
211.2K
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
1000 Skokie Boulevard · Wilmette, IL 60091 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -0.51 | -0.61 | -19.1% | 54.10 | +0.1% | -1.5% | +2.8% | +1.1% | -0.5% | -2.6% | — |
| Nov 13, 2025 | AMC | -0.46 | -0.48 | -4.3% | 87.01 | -7.5% | -10.4% | -2.0% | +5.5% | +3.0% | +0.0% | — |
| Aug 12, 2025 | AMC | -0.47 | -0.35 | +25.5% | 35.90 | -2.1% | -6.7% | +7.0% | -0.4% | -4.1% | -2.2% | — |
| May 13, 2025 | AMC | -0.65 | -0.38 | +41.5% | 33.82 | -2.5% | +9.7% | +6.6% | -6.0% | -0.7% | +0.0% | — |
| Mar 31, 2025 | AMC | -0.36 | -2.23 | -519.4% | 36.41 | -4.0% | -8.2% | +15.3% | -10.2% | -13.3% | -3.7% | — |
| Nov 8, 2024 | AMC | -0.46 | -0.37 | +19.6% | 16.88 | +3.1% | -1.3% | +3.5% | +11.5% | -5.2% | -0.8% | — |
| Aug 9, 2024 | AMC | -0.45 | -0.50 | -11.1% | 2.21 | -3.2% | +6.8% | +2.5% | -5.8% | +3.9% | -1.7% | — |
| May 9, 2024 | AMC | -0.85 | -0.50 | +41.2% | 3.56 | -11.2% | -5.6% | +0.6% | -3.6% | -8.3% | +3.3% | — |
| Mar 28, 2024 | AMC | -0.85 | -0.60 | +29.4% | 3.41 | +4.1% | -0.3% | -5.9% | +0.3% | -0.6% | -5.6% | — |
| Nov 9, 2023 | AMC | -0.95 | -0.70 | +26.3% | 2.08 | +5.8% | -11.5% | -15.2% | +5.1% | +2.4% | -0.6% | — |
| Aug 10, 2023 | AMC | -0.95 | -0.80 | +15.8% | 3.75 | +0.0% | -5.3% | -3.1% | -1.2% | -7.6% | +3.5% | — |
| May 11, 2023 | AMC | -1.00 | -0.95 | +5.0% | 4.67 | +0.0% | +0.2% | -8.1% | -0.9% | +1.6% | +1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | Chardan Capital | Maintains | Buy → Buy | — | $54.10 | $54.15 | +0.1% | -1.5% | +2.8% | +1.1% | -0.5% | -2.6% |
| Feb 23 | BTIG | Maintains | Buy → Buy | — | $55.41 | $55.47 | +0.1% | +0.7% | +3.3% | -3.5% | -1.7% | +0.3% |
| Feb 2 | BTIG | Maintains | Buy → Buy | — | $60.38 | $60.00 | -0.6% | +8.4% | +2.2% | -11.2% | -4.3% | +1.5% |
| Jan 29 | Chardan Capital | Maintains | Buy → Buy | — | $67.44 | $67.75 | +0.5% | -0.1% | -10.3% | +8.4% | +2.2% | -11.2% |
| Jan 14 | BTIG | Maintains | Buy → Buy | — | $67.04 | $66.30 | -1.1% | +3.8% | -0.8% | +1.3% | +0.5% | +0.1% |
| Nov 14 | Raymond James | Downgrade | Strong Buy → Outperform | — | $87.01 | $80.50 | -7.5% | -10.4% | -2.0% | +5.5% | +3.0% | +0.0% |
| Nov 13 | Chardan Capital | Maintains | Buy → Buy | — | $82.58 | $81.96 | -0.8% | +5.4% | -10.4% | -2.0% | +5.5% | +3.0% |
| Nov 9 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Oct 6 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $99.39 | $101.15 | +1.8% | +0.1% | -1.0% | +0.1% | +2.4% | -13.0% |
| Oct 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $84.73 | $88.92 | +4.9% | +14.7% | +2.2% | +0.1% | -1.0% | +0.1% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $76.63 | $78.29 | +2.2% | -1.0% | +7.6% | +3.7% | +14.7% | +2.2% |
| Sep 25 | BTIG | Maintains | Buy → Buy | — | $73.04 | $74.88 | +2.5% | +6.0% | -1.0% | -1.0% | +7.6% | +3.7% |
| Sep 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $73.04 | $74.88 | +2.5% | +6.0% | -1.0% | -1.0% | +7.6% | +3.7% |
| Sep 25 | Chardan Capital | Maintains | Buy → Buy | — | $73.04 | $74.88 | +2.5% | +6.0% | -1.0% | -1.0% | +7.6% | +3.7% |
| Sep 16 | Chardan Capital | Maintains | Buy → Buy | — | $54.49 | $55.70 | +2.2% | +4.6% | +16.9% | -0.6% | -4.5% | +0.6% |
| Sep 15 | BTIG | Maintains | Buy → Buy | — | $49.22 | $51.92 | +5.5% | +10.7% | +4.6% | +16.9% | -0.6% | -4.5% |
| Aug 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $32.03 | $32.04 | +0.0% | +8.7% | +3.6% | -5.3% | -0.6% | +6.7% |
| Aug 13 | Chardan Capital | Maintains | Buy → Buy | — | $35.90 | $35.13 | -2.1% | -6.7% | +7.0% | -0.4% | -4.1% | -2.2% |
| Apr 2 | Jones Trading | Downgrade | Buy → Hold | — | $33.43 | $31.70 | -5.2% | +15.3% | -10.2% | -13.3% | -3.7% | +0.1% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.41 | $34.96 | -4.0% | -8.2% | +15.3% | -10.2% | -13.3% | -3.7% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.68 | $33.76 | +6.6% | +6.3% | +16.8% | +5.4% | -19.2% | +24.8% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.88 | $17.40 | +3.1% | -1.3% | +3.5% | +11.5% | -5.2% | -0.8% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.42 | $2.67 | +10.3% | -5.8% | +3.9% | -1.7% | +2.1% | +4.2% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.56 | $3.16 | -11.2% | -5.6% | +0.6% | -3.6% | -8.3% | +3.3% |
| Apr 11 | JonesTrading | Upgrade | Hold → Buy | — | $3.20 | $3.77 | +17.8% | +20.3% | +1.6% | -3.3% | -3.7% | -9.9% |
| Jun 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.89 | $6.40 | +30.9% | +7.4% | -5.7% | -3.6% | -3.1% | +0.9% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.68 | $4.77 | +1.9% | -8.1% | -0.9% | +1.6% | +1.6% | +5.7% |
| Mar 29 | Maxim Group | Downgrade | Buy → Hold | — | $7.25 | $7.85 | +8.3% | +2.1% | -6.1% | +0.0% | +2.9% | -4.2% |
| Mar 28 | EF Hutton | Maintains | Buy → Buy | — | $14.90 | $6.75 | -54.7% | -51.3% | +2.1% | -6.1% | +0.0% | +2.9% |
| Mar 24 | EF Hutton | Maintains | Buy → Buy | — | $13.74 | $14.90 | +8.4% | +5.5% | +2.8% | -51.3% | +2.1% | -6.1% |
| Feb 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.40 | $17.35 | -5.7% | +0.5% | -3.2% | -1.4% | -5.1% | -1.5% |
| Jan 23 | EF Hutton | Maintains | Buy → Buy | — | $14.50 | $17.50 | +20.7% | +11.0% | -0.9% | +6.9% | -1.5% | +4.2% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.25 | $8.95 | -3.2% | -2.7% | -0.6% | +0.0% | +1.7% | -1.1% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.00 | $27.45 | +14.4% | -0.8% | +2.1% | +7.8% | -1.3% | -1.9% |
| Jan 28 | Roth Capital | Maintains | Buy → Buy | — | $33.00 | $55.25 | +67.4% | +28.9% | -0.7% | -5.9% | -3.1% | +4.9% |
| Sep 24 | Maxim Group | Maintains | Buy → Buy | — | $24.88 | $27.45 | +10.3% | +0.7% | +3.5% | -4.9% | +1.2% | +7.3% |
| Feb 19 | Brookline Capital | Maintains | Buy → Buy | — | $60.15 | $62.65 | +4.2% | -7.3% | -2.2% | -8.8% | +1.9% | -2.0% |
| Feb 3 | JonesTrading | Maintains | Buy → Buy | — | $71.75 | $72.25 | +0.7% | +8.1% | -2.5% | +0.3% | +1.7% | +1.2% |
No insider trades available.
8-K · 7.01
! Medium
Monopar Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Monopar Therapeutics presented Phase 3 data showing ALXN1840 demonstrated superior neurologic benefits versus standard care in neurologic Wilson disease patients, potentially supporting future regulatory approval.
Apr 20
8-K
Unknown — 8-K Filing
Monopar released its 2025 financial results and business update; investors should monitor cash runway and clinical trial progress given the company's clinical-stage status without approved revenue-generating products.
Mar 27
8-K · 7.01
! Medium
Monopar Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Monopar Therapeutics appointed Susan Rodriguez as Chief Commercial and Strategy Officer, signaling leadership strengthening ahead of potential product commercialization efforts.
Mar 2
Data updated apr 26, 2026 12:48pm
· Source: massive.com